COMPANY RESEARCHLINZESS (linaclotide) is an oral peptide with multiple disulfide bonds and a GC-C agonist acting locally in the gastrointestinal tract. Systemic bioavailability is not the primary success criterion.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
LINZESS (linaclotide) is an oral peptide with multiple disulfide bonds and a GC-C agonist acting locally in the gastrointestinal tract. Systemic bioavailability is not the primary success criterion.
Regional commercial rights clarify company coverage without creating duplicate drug programs.
2025-11-05: FDA expands LINZESS to pediatric IBS-C patients ages 7 and older
2026-05-27: LINZESS functional-constipation indication expands to children ages 2 and older
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| linaclotide / LINZESS | GC-C · IBS-C / constipation-related indications | Approved | Quantitative human results not confirmed in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
